Literature DB >> 17075048

Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes.

Toshio Hayashi1, Hisako Matsui-Hirai, Asaka Miyazaki-Akita, Akiko Fukatsu, Jun Funami, Qun-Fang Ding, Sumitra Kamalanathan, Yuichi Hattori, Louis J Ignarro, Akihisa Iguchi.   

Abstract

Senescence may contribute to the pathogenesis of atherosclerosis. Although the bioavailability of nitric oxide (NO) is limited in senescence, the effect of NO on senescence and its relationship to cardiovascular risk factors have not been investigated fully. We studied these factors by investigating senescence-associated beta-galactosidase (SA-beta-gal) and human telomerase activity in human umbilical venous endothelial cells (HUVECs). Treatment with NO donor (Z)-1-[2-(2-aminoethyl)-N-(2-aminoethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO) and transfection with endothelial NO synthase (eNOS) into HUVECs each decreased the number of SA-beta-gal positive cells and increased telomerase activity. The NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) abolished the effect of eNOS transfection. The physiological concentration of 17beta-estradiol activated hTERT, decreased SA-beta-gal-positive cells, and caused cell proliferation. However, ICI 182780, an estrogen receptor-specific antagonist, and L-NAME each inhibited these effects. Finally, we investigated the effect of NO bioavailability on high glucose-promoted cellular senescence of HUVECs. Inhibition by eNOS transfection of this cellular senescence under high glucose conditions was less pronounced. Treatment with L-arginine or L-citrulline of eNOS-transfected cells partially inhibited, and combination of L-arginine and L-citrulline with antioxidants strongly prevented, high glucose-induced cellular senescence. These data demonstrate that NO can prevent endothelial senescence, thereby contributing to the anti-senile action of estrogen. The ingestion of NO-boosting substances, including L-arginine, L-citrulline, and antioxidants, can delay endothelial senescence under high glucose. We suggest that the delay in endothelial senescence through NO and/or eNOS activation may have clinical utility in the treatment of atherosclerosis in the elderly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075048      PMCID: PMC1629003          DOI: 10.1073/pnas.0607873103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Cellular senescence after single and repeated balloon catheter denudations of rabbit carotid arteries.

Authors:  M Fenton; S Barker; D J Kurz; J D Erusalimsky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-02       Impact factor: 8.311

2.  Caveolar localization of arginine regeneration enzymes, argininosuccinate synthase, and lyase, with endothelial nitric oxide synthase.

Authors:  B R Flam; P J Hartmann; M Harrell-Booth; L P Solomonson; D C Eichler
Journal:  Nitric Oxide       Date:  2001-04       Impact factor: 4.427

3.  Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism.

Authors:  K Breitschopf; A M Zeiher; S Dimmeler
Journal:  FEBS Lett       Date:  2001-03-23       Impact factor: 4.124

Review 4.  Studies of the molecular mechanisms in the regulation of telomerase activity.

Authors:  J P Liu
Journal:  FASEB J       Date:  1999-12       Impact factor: 5.191

5.  Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation.

Authors:  L J Ignarro; G M Buga; L H Wei; P M Bauer; G Wu; P del Soldato
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

6.  Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: the health, aging and body composition study.

Authors:  H E Resnick; R I Shorr; L Kuller; L Franse; T B Harris
Journal:  J Clin Epidemiol       Date:  2001-09       Impact factor: 6.437

7.  Physiological concentration of 17beta-estradiol retards the progression of severe atherosclerosis induced by a high-cholesterol diet plus balloon catheter injury: role of NO.

Authors:  T Hayashi; M Jayachandran; D Sumi; N K Thakur; T Esaki; E Muto; H Kano; Y Asai; A Iguchi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-06       Impact factor: 8.311

8.  Temporal effects of 17beta-estradiol on caveolin-1 mRNA and protein in bovine aortic endothelial cells.

Authors:  M Jayachandran; T Hayashi; D Sumi; A Iguchi; V M Miller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-09       Impact factor: 4.733

Review 9.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.

Authors:  H Cai; D G Harrison
Journal:  Circ Res       Date:  2000-11-10       Impact factor: 17.367

10.  Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.

Authors:  S Mitchell Harman; Frederick Naftolin; Eliot A Brinton; Debra R Judelson
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

View more
  62 in total

1.  FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis.

Authors:  Kyoichiro Tsuchiya; Jun Tanaka; Yu Shuiqing; Carrie L Welch; Ronald A DePinho; Ira Tabas; Alan R Tall; Ira J Goldberg; Domenico Accili
Journal:  Cell Metab       Date:  2012-03-07       Impact factor: 27.287

Review 2.  Effects of aging on angiogenesis.

Authors:  Johanna Lähteenvuo; Anthony Rosenzweig
Journal:  Circ Res       Date:  2012-04-27       Impact factor: 17.367

Review 3.  Vascular endothelial senescence: from mechanisms to pathophysiology.

Authors:  Jorge D Erusalimsky
Journal:  J Appl Physiol (1985)       Date:  2008-11-26

4.  Sex and mortality associated with coronary artery bypass graft.

Authors:  Vito A Mannacio; Luigi Mannacio
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

5.  Time-effect relationship of extracts from ginseng, notoginseng and chuanxiong on vascular endothelial cells senescence.

Authors:  Ming Wang; Yan Lei
Journal:  Chin J Integr Med       Date:  2014-07-30       Impact factor: 1.978

6.  Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney.

Authors:  Takahiro Nakayama; Waichi Sato; Ashio Yoshimura; Li Zhang; Tomoki Kosugi; Martha Campbell-Thompson; Hideto Kojima; Byron P Croker; Takahiko Nakagawa
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

7.  Endothelial cellular senescence is inhibited by liver X receptor activation with an additional mechanism for its atheroprotection in diabetes.

Authors:  Toshio Hayashi; Hitoshi Kotani; Tomoe Yamaguchi; Kumiko Taguchi; Mayu Iida; Koichiro Ina; Morihiko Maeda; Masafumi Kuzuya; Yuichi Hattori; Louis J Ignarro
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-07       Impact factor: 11.205

8.  Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

Authors:  Amanda E Boe; Mesut Eren; Sheila B Murphy; Christine E Kamide; Atsuhiko Ichimura; David Terry; Danielle McAnally; Layton H Smith; Toshio Miyata; Douglas E Vaughan
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

9.  Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR.

Authors:  Chao-Yung Wang; Hyung-Hwan Kim; Yukio Hiroi; Naoki Sawada; Salvatore Salomone; Laura E Benjamin; Kenneth Walsh; Michael A Moskowitz; James K Liao
Journal:  Sci Signal       Date:  2009-03-17       Impact factor: 8.192

10.  Induction of cellular senescence by secretory phospholipase A2 in human dermal fibroblasts through an ROS-mediated p53 pathway.

Authors:  Hyun Jung Kim; Kwang Seok Kim; Si Hyung Kim; Suk-Hwan Baek; Hwa Young Kim; ChuHee Lee; Jae-Ryong Kim
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-03-04       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.